Related Experiment Video
Updated: Sep 20, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Clinical studies on the blockade of the renin-angiotensin-aldosterone-system
Abstract:
The clinical value of inhibition of the renin-angiotensin-aldosterone-system (RAAS) in heart failure has clearly been documented for the ACE-inhibitors as well as for the angiotensin-I-receptor blocker (AT1) by extensive intervention studies (AIRE, CONSENSUS, SAVE, ELITE II, ValHeFT and others). The additional specific vascular and renal protection, acting beyond the lowering of blood pressure, has been investigated in the past years in numerous studies in patients with arterial hypertension, often accompanied by diabetes mellitus type II. Whereas for nephroprotection, especially also in additionally present diabetes mellitus type II, study results clearly support the assumption of additional protective effects, which exceed the purely blood-pressure lowering effect; the data available for vascular protection (coronary and cerebral vessels) are insufficient.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
